TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28403598

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with Prulifloxacine, 400 mg/day for 5 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Association of D-mannose and NAC therapy, two vials/day for 7 days
Number of subjects: 80
Study: 26083704

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 12-week guided skiing program
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 31
Study: 24267043

Group type: EXPERIMENTAL
Intervention: Cayenne pepper (500 mg, 1.25 mg capsaicin)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Evodiamine (500 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 22384541

Group type: EXPERIMENTAL
Intervention: Wenshen Yangxue Granule (WSYXG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of Wenshen Yangxue Granule (WSYXG) and Clomifene Citrate (CC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clomifene Citrate (CC)
Number of subjects: 90
Study: 20088418

Group type: EXPERIMENTAL
Intervention: Acupoint group (12 cases)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-acupoint group (9 cases)
Number of subjects: 21
Study: 16427437

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (120 to 150 mg a day continuous infusion)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (prophylactic hypervolemic and hemodilution therapy plus nimodipine)
Number of subjects: 72
Study: 15203946

Group type: EXPERIMENTAL
Intervention: CD ROM home-study course
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Internet/workbook home-study course
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Classroom instruction
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Workbook home-study course
Number of subjects: 1300
Study: 11403751

Group type: EXPERIMENTAL
Intervention: Diuretic therapy
Number of subjects: 21
Study: 8989001

Group type: COMPARATOR
Intervention: 0 micrograms fentanyl
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 10 micrograms fentanyl
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 25 micrograms fentanyl
Number of subjects: 64
Study: 7901637

Group type: EXPERIMENTAL
Intervention: Homologous blood transfusion
Number of subjects: 120

Group type: COMPARATOR
Intervention: Autologous blood transfusion
Number of subjects: 120
Study: 2961362

Group type: EXPERIMENTAL
Intervention: Timolol (0-2%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L-714,465 (0-4%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (methyl cellulose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (72 micrograms)
Number of subjects: 10
Study: 31889367

Group type: EXPERIMENTAL
Intervention: Orve + wrap® blanket
Number of subjects: 129

Group type: COMPARATOR
Intervention: Forced Air Warming
Number of subjects: 129
Study: 28156253

Group type: EXPERIMENTAL
Intervention: Endovascular treatment in patients with severe carotid stenosis (≥ 70%)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Endovascular treatment in patients with less than 70% stenosis (< 70%)
Number of subjects: 278
Study: 26968165

Group type: EXPERIMENTAL
Intervention: 400 IU/day vitamin D3
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin D3
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 1200 IU/day vitamin D3
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 1600 IU/day vitamin D3
Number of subjects: 132
Study: 25097273

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 60
Study: 22906959

Group type: EXPERIMENTAL
Intervention: Quadrivalent vaccine (Gardasil; Merck)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Bivalent vaccine (Cervarix; GlaxoSmithKline)
Number of subjects: 356
Study: 20515600

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A plus upper limb therapy programme
Number of subjects: 333

Group type: COMPARATOR
Intervention: Upper limb therapy programme alone
Number of subjects: 333
Study: 18540910

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg/d) + Cognitive‐Behavioral Therapy (CBT) + medication clinic
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg/d) + BRENDA + medication clinic
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg/d) + medication clinic with limited therapeutic content
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo + Cognitive‐Behavioral Therapy (CBT) + medication clinic
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo + BRENDA + medication clinic
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo + medication clinic with limited therapeutic content
Number of subjects: 240
Study: 15982594

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) - two periods of 2-min ischemia followed by 3-min reperfusion by aortic cross-clamped.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no ischemic preconditioning).
Number of subjects: 86
Study: 12925457

Group type: EXPERIMENTAL
Intervention: HEPACOAT stent with aspirin alone
Number of subjects: 200
Study: 11078836

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conjunctival advancement
Number of subjects: 0
Study: 8791051

Group type: EXPERIMENTAL
Intervention: Transurethral Incision of the Prostate (TUIP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transurethral Resection of the Prostate (TURP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transurethral Balloon Dilatation of the Prostate (TUBDP)
Number of subjects: 60
Study: 1519989

Group type: EXPERIMENTAL
Intervention: High UAC (n = 36)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Low UAC (n = 33)
Number of subjects: 69
Study: 6337611

Group type: EXPERIMENTAL
Intervention: mianserin (30 to 90 mg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: maprotiline (75 to 225 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: placebo (1 to 3 capsules)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: maprotiline
Number of subjects: 58

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: mianserin and maprotiline
Number of subjects: 58
Study: 31295265

Group type: EXPERIMENTAL
Intervention: High identity entrepreneurship condition
Number of subjects: 72

Group type: COMPARATOR
Intervention: Low identity entrepreneurship condition
Number of subjects: 72
Study: 28362562

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg daily
Number of subjects: 946
Study: 25649338

Group type: EXPERIMENTAL
Intervention: Percutaneous electric neurostimulation (PENS) of dermatome T7 (12 sessions of 30 minutes weekly) associated with a 1,200 Kcal/day diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1,200 Kcal/day diet
Number of subjects: 60
Study: 23179965

Group type: EXPERIMENTAL
Intervention: THC (0.015 to 0.05 mg/kg)
Number of subjects: 44
Study: 21834670

Group type: EXPERIMENTAL
Intervention: 5% topical povidone-iodine
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 0.3% ciprofloxacin
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin
Number of subjects: 164
Study: 19366970

Group type: EXPERIMENTAL
Intervention: Taspoglutide 5 mg once weekly
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Taspoglutide 10 mg once weekly
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg once weekly
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Taspoglutide 10 mg once every 2 weeks
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg once every 2 weeks
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 16736432

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Number of subjects: 16

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 16
Study: 11823257

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 2214

Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 2214
Study: 10082852

Group type: EXPERIMENTAL
Intervention: Increased protein levels of BDNF (Brain-Derived Neurotrophic Factor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of BDNF with neuropeptide Y
Number of subjects: 0
Study: 8963158

Group type: EXPERIMENTAL
Intervention: Levocabastine eye drops (0.5 mg/ml, single dose)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Levocabastine eye drops (0.5 mg/ml, one drop in each eye twice daily for two weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 32
Study: 2170144

Group type: EXPERIMENTAL
Intervention: Free sucrose (morning snack)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sucrose plus fibre (morning snack)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fructose plus fibre (morning snack)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Free sucrose (afternoon snack)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No snack (morning and afternoon)
Number of subjects: 18
Study: 7429441

Group type: EXPERIMENTAL
Intervention: Winning a doubles tennis match with decisive victory
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Winning a doubles tennis match (close match)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Winning $100 in a lottery (effortless win)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Receiving M.D. degree at graduation
Number of subjects: 3
Study: 6345281

Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid 12 mg/kg
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 30970218

Group type: EXPERIMENTAL
Intervention: ω‐3 supplementation (3 g eicosapentaenoic acid, 2 g docosahexaenoic acid)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 29884161

Group type: EXPERIMENTAL
Intervention: e‐intervention group (n = 62) received a 6‐month web‐delivered intensive dietary intervention
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: e‐intervention group (n = 62)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (n = 66)
Number of subjects: 128
Study: 26589401

Group type: EXPERIMENTAL
Intervention: Supervised rehabilitation therapy (weekly sessions with facial exercises and massages, daily facial exercises at home)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Daily homework manual for ordinary postoperative facial mimic exercises (autonomously at home)
Number of subjects: 79
Study: 24656762

Group type: EXPERIMENTAL
Intervention: Continuous case management including participation in a psychoeducation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 23019939

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation with transcutaneous electrical stimulation of auricular Shenmen (TF4)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Patient-controlled sedation with transcutaneous electrical stimulation of auricular eye point
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (pressurization without electric stimulation)
Number of subjects: 180
Study: 20404762

Group type: EXPERIMENTAL
Intervention: BAR plus water (solid CHO)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: DRINK (liquid CHO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 8
Study: 19091127

Group type: EXPERIMENTAL
Intervention: 12 mg/day of astaxanthin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 15716221

Group type: EXPERIMENTAL
Intervention: CPAP educational video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 0
Study: 12094249

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) 30 mg/m² administered from days 1 to 3 and days 8 to 10, along with vincristine, prednisolone, cyclophosphamide, and L‐asparaginase, followed by three courses of consolidation and four courses of intensification
Number of subjects: 285

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Allo-BMT
Number of subjects: 285
Study: 10616629

Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia (female patients)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: First-episode schizophrenia
Number of subjects: 27

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 27
Study: 8532923

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: External high frequency oscillation around a negative baseline (EHFO‐NB)
Number of subjects: 20
Study: 2006664

Group type: EXPERIMENTAL
Intervention: Diuretics with or without methyldopa
Number of subjects: 822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study: 7005474

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 19
Study: 31625483

Group type: EXPERIMENTAL
Intervention: Tailored dietary counselling using a computer-based algorithm
Number of subjects: 80

Group type: COMPARATOR
Intervention: Generic dietary guidelines (Control)
Number of subjects: 80
Study: 31501124

Group type: EXPERIMENTAL
Intervention: Probiotic tablets containing Streptococcus salivarius M18 and Lactobacillus acidophilus with regular oral hygiene
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular oral hygiene alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Probiotic tablets
Number of subjects: 50
Study: 29669596

Group type: EXPERIMENTAL
Intervention: 12.5-μg sublingual tablets of misoprostol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo sublingual tablets and 25-μg vaginal tablets of misoprostol
Number of subjects: 140
Study: 27725525

Group type: EXPERIMENTAL
Intervention: Implantation technique using quantitative coronary angiography (QCA)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Implantation technique using optical coherence tomography (OCT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Plaque morphology
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Balloon-artery ratio
Number of subjects: 87
Study: 24698648

Group type: EXPERIMENTAL
Intervention: Standard stretching exercise intervention (n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Enhanced stretching exercise intervention (n=40)
Number of subjects: 80
Study: 22182263

Group type: EXPERIMENTAL
Intervention: Adults in the Making (AIM) program
Number of subjects: 347

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 347
Study: 21076354

Group type: EXPERIMENTAL
Intervention: Rubbed and rinsed lenses (60s at visit 1, 20s at visit 2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control lenses (directly from blister pack to storage case)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comfort scores for both test and control lenses
Number of subjects: 20
Study: 17716389

Group type: EXPERIMENTAL
Intervention: i-NPH patients
Number of subjects: 19
Study: 15980034

Group type: EXPERIMENTAL
Intervention: Borderline diabetes
Number of subjects: 2040

Group type: EXPERIMENTAL
Intervention: Diabetes without microvascular disease
Number of subjects: 2040

Group type: EXPERIMENTAL
Intervention: Diabetes with microvascular disease
Number of subjects: 2040

Group type: EXPERIMENTAL
Intervention: Higher glucose levels
Number of subjects: 2040

Group type: EXPERIMENTAL
Intervention: Subjects with microvascular complications and glucose level <7.7 mmol/L
Number of subjects: 2040
Study: 12164728

Group type: EXPERIMENTAL
Intervention: Dependence Scale scores
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Dependence level
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Change in patient dependence
Number of subjects: 230
Study: 10578025

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (Group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Total parenteral nutrition (Group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Both enteral and parenteral nutrition (Group C)
Number of subjects: 45
Study: 7485307

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (50 micrograms intravaginally)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Prostaglandin E2 (0.5 mg intracervically)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 103

Group type: COMPARATOR
Intervention: Prostaglandin E2
Number of subjects: 103
Study: 1691900

Group type: EXPERIMENTAL
Intervention: Medium-molecular-weight hydroxyethyl starch solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight hydroxyethyl starch solution
Number of subjects: 0
Study: 374194

Group type: EXPERIMENTAL
Intervention: Oral BCG vaccine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control preparation
Number of subjects: 48
Study: 31845273

Group type: EXPERIMENTAL
Intervention: 60% PP and 40% sawdust
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 70% PP and 30% sawdust
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 80% PP and 20% sawdust
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 90% PP and 10% sawdust
Number of subjects: 12
Study: 31866800

Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gd-DTPA
Number of subjects: 40
Study: 27885763

Group type: EXPERIMENTAL
Intervention: Meditation awareness training (MAT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cognitive behaviour theory for groups (active control)
Number of subjects: 74
Study: 25542393

Group type: EXPERIMENTAL
Intervention: Culprit artery occluded (TIMI 0 to 1)
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Culprit artery patent (TIMI 2 to 3)
Number of subjects: 1319
Study: 23307395

Group type: EXPERIMENTAL
Intervention: Guided Care
Number of subjects: 904

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 904
Study: 21437363

Group type: EXPERIMENTAL
Intervention: Low-salt bread (1.4% salt)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ordinary bread (2% salt)
Number of subjects: 58
Study: 18035430

Group type: EXPERIMENTAL
Intervention: Convenience sample (n=142)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Snowball sample (n=60)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Random sample (n=97)
Number of subjects: 299
Study: 16418306

Group type: EXPERIMENTAL
Intervention: Male infants
Number of subjects: 76

Group type: COMPARATOR
Intervention: Female infants
Number of subjects: 76
Study: 12594686

Group type: EXPERIMENTAL
Intervention: 4 Fr catheters
Number of subjects: 1114
Study: 10733114

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg IV every 6 hours)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 134
Study: 8835890

Group type: EXPERIMENTAL
Intervention: Cimetidine (20 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Famotidine (40 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acid-reducing therapy (all drugs)
Number of subjects: 80
Study: 1575589

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg, intramuscular injection)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (intramuscular injection)
Number of subjects: 8
Study: 3909329

Group type: EXPERIMENTAL
Intervention: Aztreonam, 2.0 g every 8‐12 hr
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 21
Study: 30597578

Group type: EXPERIMENTAL
Intervention: Imagery exposure to alcohol-related cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Binge and heavy drinkers
Number of subjects: 0
Study: 29370583

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Chemotherapy in ER-positive or luminal tumours
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Gene-set enrichment analysis
Number of subjects: 109
Study: 27079717

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 39
Study: 26135893

Group type: EXPERIMENTAL
Intervention: Caprylic acid (CA) 0.7%
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Caprylic acid (CA) 1.0%
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (0% CA)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Caprylic acid (CA) (0.7% and 1%)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Caprylic acid (CA)
Number of subjects: 2
Study: 22990330

Group type: EXPERIMENTAL
Intervention: 200 mg almorexant once daily for 9 days
Number of subjects: 14
Study: 21281434

Group type: EXPERIMENTAL
Intervention: PEG‐IFN α‐2a plus ribavirin
Number of subjects: 217

Group type: COMPARATOR
Intervention: PEG‐IFN α‐2b plus ribavirin
Number of subjects: 217
Study: 20183662

Group type: EXPERIMENTAL
Intervention: Dysfunctional Attitudes Scale
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Correlated 2‐factor model (perfectionism and need for social approval)
Number of subjects: 422
Study: 16967682

Group type: EXPERIMENTAL
Intervention: Truncal ligation of the inferior thyroid arteries during bilateral subtotal thyroidectomy
Number of subjects: 98

Group type: COMPARATOR
Intervention: No truncal ligation of the inferior thyroid arteries during bilateral subtotal thyroidectomy
Number of subjects: 98
Study: 14677608

Group type: EXPERIMENTAL
Intervention: 1100 ppm fluoride dentifrice
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: 2800 ppm fluoride dentifrice
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Caries scores on occlusal surfaces
Number of subjects: 644

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 644
Study: 11190775

Group type: EXPERIMENTAL
Intervention: 0.1% dimetindene maleate spray (Fenistil Nasal Dosierspray)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9345680

Group type: EXPERIMENTAL
Intervention: Clinical tests used in physical examination of the neck
Number of subjects: 50
Study: 8063496

Group type: EXPERIMENTAL
Intervention: Non-touch technique for tympanostomy tube insertion
Number of subjects: 66

Group type: COMPARATOR
Intervention: Touched control technique for tympanostomy tube insertion
Number of subjects: 66
Study: 3057674

Group type: EXPERIMENTAL
Intervention: Oral prazosin (2 mg twice daily) for three weeks
Number of subjects: 24